Aurobindo Pharma’s Andhra Arm Gets Form 483 With Five Observations From USFDA: What It Means for Investors
Aurobindo Pharma’s Andhra Pradesh-based Unit-IV receives Form 483 with five observations from the USFDA. What does this mean for investors and the company’s future prospects?